Sentence examples for malaria versus from inspiring English sources
In order to examine the contributions of exposure and immunity to the altered effect of ITNs and transmission intensity, we examined odds ratios for febrile malaria versus asymptomatic parasitaemia (Table 3).
Patients over 15years represented 87% of those referred cases, with an over-representation of females (10.2% of SM among females attending dispensary with malaria versus 5% of SM among males malaria cases, OR = 2.15 [1.62–2.85]), especially for patients more than 15 years old (18.3% of women versus 11.7% of men, OR = 1.62 [1.62–2.33]).
To evaluate how scores performed under different conditions, we performed stratified analyses looking at the etiology of fever (malaria versus NMFI) and time to death (early versus late).
Sub-analyses were performed in malaria versus non-malaria febrile illness (NMFI), and in early (≤48 hours) versus late (>48 hours) deaths.
White et al. (2009) reported leakage of fibrinogen from retinal vessels in 31% (11/35) of cases with cerebral malaria versus 7% (2/29) coma of other cause.
Because the effect of perceptions (susceptibility, severity, benefits and barriers) was important, we analyzed the odds ratio for each variable for malaria-affected versus malaria-unaffected MVs separately.
In malaria-endemic areas, to assess the effects in pregnant women of: Malaria chemoprevention versus no chemoprevention irrespective of the regimen; Malaria chemoprevention with SP (called intermittent preventive treatment) with no chemoprevention; Preventive regimens for Plasmodium vivax.
On day 15 the estimated marginal mean of 58Fe incorporation was 14.4% (95% CI: 9.7 21.1) in the malaria group versus 25.9% 955% CI: 17.5 38.4) in the non-malaria anaemic group.
The 99bp allele in the polymorphic repeat centred on codon 667 of Rh1 was more common in severe than mild malaria (12% versus 4%), with an OR of 3.14 (95% CI 1.20 8.19) compared to the most common allele (P = 0.02).
For the secondary vaccine efficacy endpoint, the study had 90% power to detect significant (p<0.05) vaccine efficacy of either candidate malaria vaccine versus control assuming an infection rate of 72% over the 14 week period for surveillance of infection and a true vaccine efficacy of 45%.
